List of RaQualia Pharma patents | 8 results

Name	Description	Patent Applicant	Current Assignee	Patent Jurisdiction	Patent Number	Date of Patent
‌ US Patent 7479564 Aryl or heteroaryl fused imidazole compounds as anti-inflammatory and analgesic agents	Patent 7479564 was granted and assigned to RaQualia Pharma on January, 2009 by the United States Patent and Trademark Office.		‌ RaQualia Pharma	United States Patent and Trademark Office	7479564	January 20, 2009
‌ US Patent 7723321 Chromane substituted benzimidazole derivatives	Patent 7723321 was granted and assigned to RaQualia Pharma on May, 2010 by the United States Patent and Trademark Office.		‌ RaQualia Pharma	United States Patent and Trademark Office	7723321	May 25, 2010
‌ US Patent 8084476 Substituted methyl aryl or heteroaryl amide compounds	Patent 8084476 was granted and assigned to RaQualia Pharma on December, 2011 by the United States Patent and Trademark Office.		‌ RaQualia Pharma	United States Patent and Trademark Office	8084476	December 27, 2011
‌ US Patent 11154544 Amide derivatives as Nav1.7 and Nav1.8 blockers	Patent 11154544 was granted and assigned to RaQualia Pharma on October, 2021 by the United States Patent and Trademark Office.	‌ RaQualia Pharma	‌ RaQualia Pharma	United States Patent and Trademark Office	11154544	October 26, 2021
‌ US Patent 7718809 Chromane substituted benzimidazole derivatives as acid pump antagonists	Patent 7718809 was granted and assigned to RaQualia Pharma on May, 2010 by the United States Patent and Trademark Office.		‌ RaQualia Pharma	United States Patent and Trademark Office	7718809	May 18, 2010
‌ US Patent 8466166 Benzimidazole derivatives as selective acid pump inhibitors	Patent 8466166 was granted and assigned to RaQualia Pharma on June, 2013 by the United States Patent and Trademark Office.		‌ RaQualia Pharma	United States Patent and Trademark Office	8466166	June 18, 2013
‌ US Patent 11135270 Method for preventing or treating heart failure by administering a medicament containing an antagonist of corticotropin releasing hormone receptor 2 (CRHR2)	Patent 11135270 was granted and assigned to RaQualia Pharma on October, 2021 by the United States Patent and Trademark Office.	‌ RaQualia Pharma	‌ RaQualia Pharma	United States Patent and Trademark Office	11135270	October 5, 2021
‌ US Patent 11802120 Fused cyclic urea derivatives as CRHR2 antagonist	Patent 11802120 was granted and assigned to RaQualia Pharma on October, 2023 by the United States Patent and Trademark Office.		‌ RaQualia Pharma	United States Patent and Trademark Office	11802120	October 31, 2023